Respire Diagnostics have a vision that quantification of biomarkers in exhaled breath will be the next generation of medical diagnostics. We have developed and patented a low-cost, connected breath analyser to target Chronic Obstructive Pulmonary Disease (COPD). It is a progressive and irreversible condition that affects 384 million patients and the 3rd leading cause of death worldwide. Discussions with key opinion leaders, clinicians and patients uncovered the compelling need to obviate the current invasive, costly and untimely diagnosis methods employed. Early diagnosis, long-term monitoring in conjunction with timely treatment can retard progressiveness and reduce the mortality rate by over 80%.